20060611
 FDA Seeks More Data on New Migraine Drug   The Wall Street Journal,  Jun 12, 2006  If approved, some analysts have predicted Trexima's annual sales would quickly reach $1 billion. The drug is a combination of sumatriptan -- the active ingredient in GlaxoSmithKline's current blockbuster migraine drug Imitrex -- and naproxen sodium, the active ingredient in many common pain medicines such as Aleve.   
